

Claudia Sommerer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/38337/publications.pdf>

Version: 2024-02-01

102
papers

3,357
citations

159585

30
h-index

161849

54
g-index

104
all docs

104
docs citations

104
times ranked

3247
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Therapeutic Drug Monitoring, 2019, 41, 261-307.	2.0	374
2	Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet, The, 2011, 377, 837-847.	13.7	326
3	Comparing Mycophenolate Mofetil Regimens for de Novo Renal Transplant Recipients: The Fixed-Dose Concentration-Controlled Trial. Transplantation, 2008, 86, 1043-1051.	1.0	238
4	Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation. Journal of the American Society of Nephrology: JASN, 2018, 29, 1979-1991.	6.1	193
5	After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney International, 2020, 98, 1044-1052.	5.2	103
6	Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study. American Journal of Transplantation, 2019, 19, 3018-3034.	4.7	97
7	Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation. Therapeutic Drug Monitoring, 2016, 38, S1-S20.	2.0	78
8	Pharmacodynamic Monitoring of Cyclosporine A in Renal Allograft Recipients Shows a Quantitative Relationship Between Immunosuppression and the Occurrence of Recurrent Infections and Malignancies. Transplantation, 2006, 82, 1280-1285.	1.0	75
9	An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de-novo kidney transplant patients. Kidney International, 2019, 96, 231-244.	5.2	69
10	Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study. Transplantation, 2019, 103, 1953-1963.	1.0	69
11	Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy. Journal of the American Society of Nephrology: JASN, 2018, 29, 317-325.	6.1	64
12	Ciclosporin A Tapering Monitored by NFAT-Regulated Gene Expression: A New Concept of Individual Immunosuppression. Transplantation, 2008, 85, 15-21.	1.0	60
13	Living donor kidney transplantation in crossmatch-positive patients enabled by peritransplant immunoadsorption and anti-CD20 therapy. Transplant International, 2012, 25, 506-517.	1.6	59
14	Assessment of renal allograft fibrosis by transient elastography. Transplant International, 2013, 26, 545-551.	1.6	58
15	Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. British Journal of Clinical Pharmacology, 2010, 69, 346-357.	2.4	57
16	Biomarkers as a Tool for Management of Immunosuppression in Transplant Patients. Therapeutic Drug Monitoring, 2010, 32, 560-572.	2.0	54
17	Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients. Journal of Hypertension, 2008, 26, 2213-2219.	0.5	50
18	Urinary miR-155-5p and CXCL10 as prognostic and predictive biomarkers of rejection, graft outcome and treatment response in kidney transplantation. British Journal of Clinical Pharmacology, 2017, 83, 2636-2650.	2.4	49

#	ARTICLE	IF	CITATIONS
19	Individualized Monitoring of Nuclear Factor of Activated T Cells-Regulated Gene Expression in FK506-Treated Kidney Transplant Recipients. <i>Transplantation</i> , 2010, 89, 1417-1423.	1.0	43
20	Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil. <i>Rheumatology</i> , 2010, 49, 2061-2067.	1.9	41
21	Calcineurin inhibitors and NFAT-regulated gene expression. <i>Clinica Chimica Acta</i> , 2012, 413, 1379-1386.	1.1	41
22	Pharmacokinetics and Pharmacodynamics of Intensified versus Standard Dosing of Mycophenolate Sodium in Renal Transplant Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 503-511.	4.5	40
23	Pharmacodynamic immune monitoring of NFAT-regulated genes predicts skin cancer in elderly long-term renal transplant recipients. <i>Clinical Transplantation</i> , 2008, 22, 549-554.	1.6	39
24	Pharmacodynamic monitoring of calcineurin inhibitor therapy: Is there a clinical benefit?. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 21-27.	0.7	39
25	Pharmacodynamic cyclosporine A-monitoring: relation of gene expression in lymphocytes to cyclosporine blood levels in cardiac allograft recipients. <i>Transplant International</i> , 2007, 20, 1036-1043.	1.6	35
26	Overhydration Is a Strong Predictor of Mortality in Peritoneal Dialysis Patients “ Independently of Cardiac Failure. <i>PLoS ONE</i> , 2016, 11, e0158741.	2.5	34
27	End-stage renal disease, dialysis, kidney transplantation and their impact on CD^4 T-cell differentiation. <i>Immunology</i> , 2018, 155, 211-224.	4.4	34
28	Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study. <i>Clinical Nephrology</i> , 2015, 83 (2015), 11-21.	0.7	33
29	Pharmacodynamic Monitoring of Cyclosporin A Reveals Risk of Opportunistic Infections and Malignancies in Renal Transplant Recipients 65 Years and Older. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 694-698.	2.0	32
30	Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 1060-1070.	0.7	31
31	Clinical validation of a novel enzyme-linked immunosorbent spot assay-based <i>in vitro</i> diagnostic assay to monitor cytomegalovirus-specific cell-mediated immunity in kidney transplant recipients: a multicenter, longitudinal, prospective, observational study. <i>Transplant International</i> , 2018, 31, 436-450.	1.6	30
32	Phase I trial of donor-derived modified immune cell infusion in kidney transplantation. <i>Journal of Clinical Investigation</i> , 2020, 130, 2364-2376.	8.2	29
33	The long-term consequences of living-related or unrelated kidney donation. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, iv45-iv47.	0.7	28
34	Cyclosporin A Toxicity of the Renal Allograft “ a Late Complication and Potentially Reversible. <i>Nephron</i> , 2002, 92, 339-345.	1.8	27
35	Role of FTY720 on M1 and M2 macrophages, lymphocytes, and chemokines in atchmode documentclass[fleqn,10pt,legalpaper]{article} usepackage{amssymb} usepackage{amsfonts} usepackage{amsmath} pagestyle{empty} egin{document} (5/6) end{document} nephrectomized rats. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 297, F769-F780.	2.7	26
36	Safety and Efficacy of Intensified Versus Standard Dosing Regimens of Enteric-Coated Mycophenolate Sodium in De Novo Renal Transplant Patients. <i>Transplantation</i> , 2011, 91, 779-785.	1.0	26

#	ARTICLE	IF	CITATIONS
37	Immunomonitoring of nuclear factor of activated T cells-regulated gene expression: The first clinical trial in liver allograft recipients. <i>Liver Transplantation</i> , 2011, 17, 466-473.	2.4	26
38	Psychosocial and physical outcome following kidney donation-a retrospective analysis. <i>Transplant International</i> , 2015, 28, 416-428.	1.6	26
39	Pharmacodynamic Disparities in Tacrolimus-Treated Patients Developing Cytomegalus Virus Viremia. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 373-379.	2.0	25
40	Association of Serum Uromodulin with Death, Cardiovascular Events, and Kidney Failure in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 616-624.	4.5	25
41	Pharmacodynamic monitoring of nuclear factor of activated T cell-regulated gene expression in liver allograft recipients on immunosuppressive therapy with calcineurin inhibitors in the course of time and correlation with acute rejection episodes â€” a prospective study. <i>Annals of Transplantation</i> , 2014, 19, 32-40.	0.9	25
42	Application of the iBox prognostication system as a surrogate endpoint in the TRANSFORM randomised controlled trial: proof-of-concept study. <i>BMJ Open</i> , 2021, 11, e052138.	1.9	24
43	Nuclear Factor of Activated T Cellsâ€”Regulated Gene Expression as Predictive Biomarker of Personal Response to Calcineurin Inhibitors. <i>Therapeutic Drug Monitoring</i> , 2016, 38, S50-S56.	2.0	21
44	Everolimus immunosuppression in kidney transplantation: What is the optimal strategy?. <i>Transplantation Reviews</i> , 2016, 30, 3-12.	2.9	21
45	Pharmacodynamic monitoring of cyclosporine A by NFATâ€”regulated gene expression and the relationship with infectious complications in pediatric renal transplant recipients. <i>Pediatric Transplantation</i> , 2010, 14, 844-851.	1.0	20
46	Blood pressure control in chronic kidney disease: A cross-sectional analysis from the German Chronic Kidney Disease (GCKD) study. <i>PLoS ONE</i> , 2018, 13, e0202604.	2.5	20
47	Cardiac Biomarkers in Haemodialysis Patients: The Prognostic Value of Amino-Terminal Pro-B-Type Natriuretic Peptide and Cardiac Troponin T. <i>Nephron Clinical Practice</i> , 2007, 107, c77-c81.	2.3	18
48	Monitoring immunosuppression with measures of NFAT decreases cancer incidence. <i>Clinical Immunology</i> , 2009, 132, 305-311.	3.2	18
49	Glycaemic control and antidiabetic therapy in patients with diabetes mellitus and chronic kidney disease â€” cross-sectional data from the German Chronic Kidney Disease (GCKD) cohort. <i>BMC Nephrology</i> , 2016, 17, 59.	1.8	18
50	Outcomes and complications following ABOâ€”incompatible kidney transplantation performed after desensitization by semiâ€”selective immunoabsorption â€” a retrospective study. <i>Transplant International</i> , 2019, 32, 1286-1296.	1.6	18
51	Renal function to 5Â”years after late conversion of kidney transplant patients to everolimus: a randomized trial. <i>Journal of Nephrology</i> , 2015, 28, 115-123.	2.0	16
52	Status of periodontal health in German patients suffering from chronic kidney diseaseâ€”Data from the GCKD study. <i>Journal of Clinical Periodontology</i> , 2020, 47, 19-29.	4.9	15
53	Novel Biomarkers in Patients with Chronic Kidney Disease: An Analysis of Patients Enrolled in the GCKD-Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 886.	2.4	15
54	Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials. <i>BMC Nephrology</i> , 2018, 19, 237.	1.8	14

#	ARTICLE	IF	CITATIONS
55	The Calcineurin Inhibitor-Sparing (CIS) Trial - individualised calcineurin-inhibitor treatment by immunomonitoring in renal allograft recipients: protocol for a randomised controlled trial. <i>Trials</i> , 2014, 15, 489.	1.6	13
56	Evolution of allograft fibrosis and function in kidney transplant recipients: a retrospective analysis of stable patients under CNI and mTORi. <i>Transplant International</i> , 2015, 28, 553-564.	1.6	12
57	Evidence-based practice: Guidance for using everolimus in combination with low-exposure calcineurin inhibitors as initial immunosuppression in kidney transplant patients. <i>Transplantation Reviews</i> , 2019, 33, 191-199.	2.9	12
58	Should kidney allografts from old donors be allocated only to old recipients?. <i>Transplant International</i> , 2020, 33, 849-857.	1.6	12
59	Correlation between pharmacokinetics of tacrolimus and pharmacodynamics on NFAT-regulated gene expression in stable kidney transplant recipients. <i>Clinical Nephrology</i> , 2017, 87, 93-99.	0.7	12
60	Design and rationale of the ATHENA study – A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial. <i>Trials</i> , 2016, 17, 92.	1.6	11
61	Switch to an everolimus-facilitated cyclosporine A sparing immunosuppression improves glycemic control in selected kidney transplant recipients. <i>Clinical Transplantation</i> , 2017, 31, e13024.	1.6	11
62	Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy. <i>American Journal of Transplantation</i> , 2018, 18, 2965-2976.	4.7	11
63	AEB071 – a promising immunosuppressive agent. <i>Clinical Transplantation</i> , 2009, 23, 15-18.	1.6	10
64	Approaches towards Individualized Immune Intervention. <i>Digestive Diseases</i> , 2010, 28, 45-50.	1.9	10
65	High interpatient variability in response to mycophenolic acid maintenance therapy in patients with ANCA-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, i138-i145.	0.7	10
66	Gender disparity in health-related quality of life and fatigue after living renal donation. <i>BMC Nephrology</i> , 2018, 19, 377.	1.8	10
67	Cyclosporine-induced gingival overgrowth correlates with NFAT-regulated gene expression: a pilot study. <i>Journal of Clinical Periodontology</i> , 2011, 38, 984-991.	4.9	9
68	Secreted frizzled-related protein 4 predicts progression of autosomal dominant polycystic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2015, 31, gfv077.	0.7	9
69	Effect of everolimus-based drug regimens on CMV-specific T-cell functionality after renal transplantation: 12-month ATHENA subcohort study results. <i>European Journal of Immunology</i> , 2021, 51, 943-955.	2.9	9
70	Early prognostic performance of miR155-5p monitoring for the risk of rejection: Logistic regression with a population pharmacokinetic approach in adult kidney transplant patients. <i>PLoS ONE</i> , 2021, 16, e0245880.	2.5	9
71	Monitoring of calcineurin inhibitors by NFAT-regulated gene expression in de novo renal allograft recipients on cyclosporine A. <i>Clinical Nephrology</i> , 2015, 84 (2015), 165-172.	0.7	9
72	Early conversion from cyclosporine to everolimus following living-donor kidney transplantation: outcomes at 5 years posttransplant in the randomized ZEUS trial. <i>Clinical Nephrology</i> , 2016, 85 (2016), 215-225.	0.7	9

#	ARTICLE	IF	CITATIONS
73	Analytical Validation and Cross-Validation of an NFAT-Regulated Gene Expression Assay for Pharmacodynamic Monitoring of Therapy With Calcineurin Inhibitors. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 711-716.	2.0	8
74	Soluble urokinase plasminogen activation receptor and long-term outcomes in persons undergoing coronary angiography. <i>Scientific Reports</i> , 2019, 9, 475.	3.3	8
75	Peptide Vaccination against Cytomegalovirus Induces Specific T Cell Response in Responses in CMV Seronegative End-Stage Renal Disease Patients. <i>Vaccines</i> , 2021, 9, 133.	4.4	8
76	Educational Attainment Is Associated With Kidney and Cardiovascular Outcomes in the German CKD (GCKD) Cohort. <i>Kidney International Reports</i> , 2022, 7, 1004-1015.	0.8	8
77	Improved Pulse Wave Velocity and Renal Function in Individualized Calcineurin Inhibitor Treatment by Immunomonitoring. <i>Transplantation</i> , 2018, 102, 510-520.	1.0	7
78	Everolimus in de novo kidney transplant recipients participating in the Eurotransplant senior program: Results of a prospective randomized multicenter study (SENATOR). <i>PLoS ONE</i> , 2019, 14, e0222730.	2.5	7
79	A need-adapted transition program after pediatric kidney transplantation. <i>Journal of Transition Medicine</i> , 2019, 1, .	0.5	7
80	Incidences of Infectious Events in a Renal Transplant Cohort of the German Center of Infectious Diseases (DZIF). <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	7
81	Analytical Aspects of the Implementation of Biomarkers in Clinical Transplantation. <i>Therapeutic Drug Monitoring</i> , 2016, 38, S80-S92.	2.0	6
82	Target Enzyme Activity and Phosphorylation of Pathway Molecules As Specific Biomarkers in Transplantation. <i>Therapeutic Drug Monitoring</i> , 2016, 38, S43-S49.	2.0	6
83	An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 799-807.	1.8	6
84	The role of age-related T cell differentiation in patients with renal replacement therapy. <i>Immunology and Cell Biology</i> , 2017, 95, 895-905.	2.3	6
85	Monitoring of gene expression in tacrolimus-treated de novo renal allograft recipients facilitates individualized immunosuppression: Results of the IMAGEN study. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3851-3862.	2.4	6
86	Advantages of plasmatic CXCL-10 as a prognostic and diagnostic biomarker for the risk of rejection and subclinical rejection in kidney transplantation. <i>Clinical Immunology</i> , 2021, 229, 108792.	3.2	6
87	Bioimpedance analysis is not superior to clinical assessment in determining hydration status: A prospective randomized-controlled trial in a Western dialysis population. <i>Hemodialysis International</i> , 2021, 25, 380-390.	0.9	4
88	New concepts to individualize calcineurin inhibitor therapy in renal allograft recipients. <i>Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia</i> , 2010, 21, 1030-7.	0.3	4
89	Reporting Quality-of-Life Outcomes in Clinical Trials of Immunosuppressive Therapy in Kidney Transplantation. <i>American Journal of Kidney Diseases</i> , 2016, 67, 722-723.	1.9	3
90	Histological findings to five years after early conversion of kidney transplant patients from cyclosporine to everolimus: an analysis from the randomized ZEUS study. <i>BMC Nephrology</i> , 2018, 19, 154.	1.8	3

#	ARTICLE	IF	CITATIONS
91	Effectiveness of different immunoadsorption columns for anti-A/B antibody depletion. <i>Atherosclerosis Supplements</i> , 2019, 40, 68-72.	1.2	3
92	Living Donor Kidney Transplantation in Patients With Donor-Specific HLA Antibodies After Desensitization With Immunoadsorption. <i>Frontiers in Medicine</i> , 2021, 8, 781491.	2.6	3
93	Current pharmacotherapeutical options for the prevention of kidney transplant rejection. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1029-1041.	1.8	2
94	Soluble Urokinase Receptor and Mortality in Kidney Transplant Recipients. <i>Transplant International</i> , 2021, 35, 10071.	1.6	2
95	Spectrum and dosing of urate-lowering drugs in a large cohort of chronic kidney disease patients and their effect on serum urate levels: a cross-sectional analysis from the German Chronic Kidney Disease study. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 277-283.	2.9	1
96	Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination against CMV. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1029.	4.1	1
97	Rapid deterioration of renal function in a long-term allograft recipient with recurrent IgA nephritis is it the only cause?. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 3079-3081.	0.7	0
98	1575. Clinical Validation of a Novel ELISpot-based in vitro Diagnostic Assay to Monitor CMV-Specific Cell-Mediated Immunity in SOT and HSCT Immunocompromised Patients. <i>Open Forum Infectious Diseases</i> , 2018, 5, S491-S492.	0.9	0
99	7â€¦Modified immune cell therapy ameliorates murine lupus nephritis and induces regulatory cell subsets. , 2019, , .		0
100	OP0040â€¦MODIFIED IMMUNE CELL THERAPY AMELIORATES MURINE LUPUS NEPHRITIS AND INDUCES REGULATORY CELL SUBSETS. , 2019, , .		0
101	P0782PROGNOSTIC IMPACT OF NECK CIRCUMFERENCE ON CARDIVASCULAR OUTCOMES AND MORTALITY IN PATIENTS WITH MODERATE CHRONIC KIDNEY DISEASE: AN ANALYSIS FROM THE GERMAN CHRONIC KIDNEY DISEASE (GCKD) STUDY. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
102	Induction of Donor-Specific Immune Tolerance with Clinical MIC Cell Infusion â€” a Phase I Study (TOL-1). <i>Blood</i> , 2018, 132, 4539-4539.	1.4	0